In 2026, boards won’t ask if you use AI — they’ll ask if you truly understand, control, and can explain how it’s steering the ...
Company remains focused on potential approval and launch of IGALMI® for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting NEW HAVEN, Conn., Jan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback